Medgenics is a clinical-stage biopharmaceutical company that is developing and commercializing Biopump, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient’s own tissue for the treatment of a range of chronic diseases. These diseases include anemia, hepatitis, and hemophilia, among others.
The company announced today that it will be presenting a poster at the upcoming American Society of Nephrology’s Kidney Week 2012, taking place in San Francisco from October 30 to November 4. The poster is titled “Novel Sustained delivery of Erythropoietin in Hemodialysis Patients for Safer Anemia Control Using EPODURE Biopumps – Autologous Dermal Tissue Samples Secreting Erythropoitein.”
The poster will present preliminary data from a Phase IIa clinical trial of EPODURE to treat anemia patients with end stage renal disease. EPODURE is an autologous dermal Biopump, implanted subcutaneously, capable of the sustained secretion of therapeutic erythropoitein (EPO) in the body using a small tissue explant from the patient’s own skin and processed to continuously produce EPO for many months.
Medgenics poster will actually be presented on Friday, November 2. It aims to bring this Biopump and others to market via strategic partnerships with major pharmaceutical and medical device companies.
For additional information about Medgenics and its proprietary Biopump technology, please visit www.medgenics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment